UNSPSC 51372901: Bezitramide

This classification denotes an analgesic agent with the molecular formula C31H32N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3KXW0Y310I, chemically known as 2-benzimidazolinone, 1-(1-(3-cyano-3,3-diphenylpropyl)-4-piperidyl)-3-propionyl- but generally known as bezitramide, which bears US NIH Compound Identifier 61791. European Medicines Agency schedules Bezitramide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05811MIG. The term BEZITRAMIDE is an International Non-Proprietary Name.

UNSPSC 51372901 Bezitramide is a Commodity code that in practice captures procurement of naloxone and related drug-response products by state and local health authorities. The recent solicitation record shows that state and local governments are buying naloxone (opioid antagonist) and safe drug deactivation systems to support overdose response and community health initiatives. Seminole County, Florida, the issuing body in the recent record, procures these products through competitive bidding to stock community health facilities and support harm-reduction programs. The scope includes unit pricing, quarterly delivery schedules, shipping included in bid proposals, and standard compliance requirements such as drug-free workplace certification, E-Verify authorization, workers' compensation insurance, and commercial general liability coverage. Contracts are typically structured with multi-year initial terms and renewal options.

The geographic spread of recent activity is narrow: the available record shows only Seminole County, Florida. A single recent IFB (Solicitation Number IFB60459723LAS) posted June 30, 2026, with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for delivery to the Seminole County Community Health Building in Sanford, Florida. The procurement carried potential FEMA funding and included a three-month probationary termination provision. The code shows minimal recent state and local activity in the available dataset; practitioners should monitor for additional opioid-antagonist and harm-reduction procurement across state health departments and county public health offices, particularly in jurisdictions with active overdose-response programs.